Rhythm Pharmaceuticals (RYTM) Financials

$93.72 +2.41 (+2.64%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$93.70 -0.02 (-0.02%)

As of 04:01 AM Eastern

Annual Income Statements for Rhythm Pharmaceuticals

This table shows Rhythm Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-12	-29	-38	-74	-281	-134	-70	-181	-185	-265	-202
Consolidated Net Income / (Loss)	-11	-26	-34	-74	-141	-134	-70	-181	-185	-261	-197
Net Income / (Loss) Continuing Operations	-11	-26	-34	-74	0.00	-134	-70	-182	-185	-261	-197
Total Pre-Tax Income	-11	-26	-34	-74	-281	-134	-70	-181	-184	-260	-196
Total Operating Income	-11	-26	-32	-78	-146	-137	-170	-179	-184	-266	-192
Total Gross Profit	0.00	0.00	0.00	0.00	0.00	0.00	2.56	22	68	117	170
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00	3.15	24	77	130	190
Operating Revenue	-	-	-	-	0.00	0.00	3.15	24	77	130	190
Total Cost of Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.60	2.13	9.30	13	19
Operating Cost of Revenue	-	-	-	-	0.00	0.00	0.60	2.13	9.30	13	19
Total Operating Expenses	11	26	32	78	292	137	173	201	252	382	362
Selling, General & Admin Expense	3.43	6.31	9.52	28	37	46	68	92	118	144	195
Research & Development Expense	7.15	20	23	50	109	90	104	109	135	238	167
Total Other Income / (Expense), net	-0.50	0.03	-1.30	4.35	11	2.58	100	-1.17	0.24	5.25	-4.03
Interest Expense	-	-	-	-	-	0.00	0.00	5.20	14	21	21
Interest & Investment Income	0.00	0.03	0.57	4.35	5.27	2.58	0.45	4.03	14	15	15
Other Income / (Expense), net	-0.50	0.00	-1.86	-	5.27	0.00	100	0.00	0.19	11	1.26
Income Tax Expense	-	-	-	-	-	-	0.00	0.00	0.56	0.35	0.50
Preferred Stock Dividends Declared	-	-	-	-	-	-	-	0.00	0.00	3.97	5.38
Basic Earnings per Share	($1.18)	($2.85)	($2.83)	($2.39)	($3.86)	($3.04)	($1.40)	($3.47)	($3.20)	($4.34)	($3.11)
Weighted Average Basic Shares Outstanding	10.20M	10.20M	13.27M	31.00M	36.42M	44.13M	49.60M	52.12M	57.67M	61.00M	64.98M
Diluted Earnings per Share	($1.18)	($2.85)	($2.83)	($2.39)	($3.86)	($3.04)	($1.40)	$0.00	($3.20)	($4.34)	($3.11)
Weighted Average Diluted Shares Outstanding	10.20M	10.20M	13.27M	31.00M	36.42M	44.13M	49.60M	0.00	57.67M	61.00M	64.98M
Weighted Average Basic & Diluted Shares Outstanding	10.20M	10.20M	13.27M	31.00M	36.42M	44.13M	49.60M	56.75M	60.14M	63.22M	68.29M

This table shows Rhythm Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Income / (Loss) Attributable to Common Shareholders	-44	-42	-141	-34	-45	-45	-51	-48	-54	-49	-57
Consolidated Net Income / (Loss)	-44	-42	-141	-32	-44	-43	-49	-47	-53	-48	-56
Net Income / (Loss) Continuing Operations	-44	-41	-141	-32	-44	-41	-49	-47	-53	-48	-56
Total Pre-Tax Income	-44	-41	-141	-32	-44	-43	-49	-46	-53	-48	-55
Total Operating Income	-44	-41	-140	-40	-44	-41	-47	-45	-53	-47	-52
Total Gross Profit	20	21	23	26	29	38	29	43	46	52	53
Total Revenue	23	24	26	29	33	42	33	49	51	57	60
Operating Revenue	23	24	26	29	33	42	33	49	51	57	60
Total Cost of Revenue	2.41	3.23	2.81	2.95	3.83	3.79	3.65	5.54	5.50	4.80	7.16
Operating Cost of Revenue	2.41	3.23	2.81	2.95	3.83	3.79	3.65	5.54	5.50	4.80	7.16
Total Operating Expenses	64	62	163	67	73	79	76	88	98	100	105
Selling, General & Admin Expense	30	32	34	36	35	38	39	46	52	57	64
Research & Development Expense	34	30	129	30	38	41	37	42	46	42	42
Total Other Income / (Expense), net	0.16	-0.36	-1.19	8.70	-0.10	-4.40	-2.41	-1.00	-0.14	-0.47	-2.73
Interest Expense	3.15	4.38	4.76	4.60	5.24	6.00	5.41	5.82	4.74	4.62	4.58
Interest & Investment Income	3.47	3.82	3.05	4.10	4.05	3.51	3.64	3.24	4.33	4.08	3.55
Other Income / (Expense), net	-0.16	0.20	0.52	9.20	1.09	-1.91	-0.64	1.58	0.27	0.06	-1.70
Income Tax Expense	0.37	0.20	0.30	0.48	-0.34	-0.09	0.08	0.34	0.11	-0.03	0.55
Preferred Stock Dividends Declared	0.00	-	0.00	1.30	1.33	-	1.32	1.35	1.38	1.33	1.10
Basic Earnings per Share	($0.76)	($0.70)	($2.35)	($0.55)	($0.73)	($0.71)	($0.81)	($0.75)	($0.82)	($0.73)	($0.83)
Weighted Average Basic Shares Outstanding	57.87M	57.67M	60.14M	61.01M	61.22M	61.00M	63.06M	63.68M	66.26M	64.98M	67.97M
Diluted Earnings per Share	($0.76)	-	($2.35)	($0.55)	($0.73)	-	($0.81)	($0.75)	($0.82)	($0.73)	($0.83)
Weighted Average Diluted Shares Outstanding	57.87M	57.67M	60.14M	61.01M	61.22M	61.00M	63.06M	63.68M	66.26M	64.98M	67.97M
Weighted Average Basic & Diluted Shares Outstanding	59.10M	60.14M	60.97M	61.13M	61.46M	63.22M	63.62M	66.42M	66.74M	68.29M	68.53M

This table details how cash moves in and out of Rhythm Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Net Change in Cash & Equivalents	35	-28	28	15	13	39	-42	68	-68	29	-35
Net Cash From Operating Activities	-6.98	-23	-29	-62	-123	-122	-146	-173	-136	-114	-116
Net Cash From Continuing Operating Activities	-6.98	-23	-29	-62	-123	-122	-146	-173	-136	-114	-116
Net Income / (Loss) Continuing Operations	-11	-26	-34	-74	-141	-134	-70	-181	-185	-261	-197
Consolidated Net Income / (Loss)	-11	-26	-34	-74	-141	-134	-70	-181	-185	-261	-197
Depreciation Expense	0.00	0.14	0.22	0.44	0.83	0.69	1.16	1.67	1.76	1.56	1.34
Amortization Expense	-	-	-	-	-	0.00	0.00	-2.31	-9.84	-8.17	-6.52
Non-Cash Adjustments To Reconcile Net Income	1.72	1.31	4.07	11	13	17	-79	26	52	144	88
Changes in Operating Assets and Liabilities, net	2.38	1.20	-0.04	0.67	4.13	-5.90	1.90	-18	4.62	9.16	-1.88
Net Cash From Investing Activities	-0.02	-5.11	-110	-87	-28	159	-62	28	-5.67	-48	-137
Net Cash From Continuing Investing Activities	-0.02	-5.11	-110	-87	-28	159	-62	28	-5.67	-48	-137
Purchase of Property, Plant & Equipment	-0.02	-1.06	-0.13	-0.72	-3.39	-0.21	-0.43	-0.28	-0.05	0.00	-0.95
Acquisitions	-	-	-	-	-	-	0.00	0.00	-5.67	-41	-40
Purchase of Investments	0.00	-15	-127	-249	-296	-87	-525	-252	-355	-268	-349
Sale and/or Maturity of Investments	0.00	11	17	162	271	246	361	284	355	261	252
Net Cash From Financing Activities	42	0.00	167	165	163	2.01	166	214	74	191	218
Net Cash From Continuing Financing Activities	42	0.00	167	165	163	2.01	166	214	74	191	218
Repayment of Debt	-	-	-	-	-	-	0.00	0.00	-7.40	-13	-20
Issuance of Debt	-	-	-	-	-	0.00	0.00	72	24	0.00	0.00
Issuance of Preferred Equity	40	0.00	0.70	-	-	-	-	0.00	0.00	139	0.00
Issuance of Common Equity	0.00	0.00	126	163	162	0.52	162	132	50	40	224
Other Financing Activities, net	2.09	0.00	41	1.81	1.56	1.49	4.13	9.75	7.47	25	14
Effect of Exchange Rate Changes	-	-	-	-	-	-	0.00	0.00	-0.14	0.00	0.09

This table details how cash moves in and out of Rhythm Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
Net Change in Cash & Equivalents	-51	-4.51	-6.52	108	-114	42	17	30	-83	2.07	7.92
Net Cash From Operating Activities	-29	-29	-41	-29	-25	-19	-40	-23	-27	-25	-44
Net Cash From Continuing Operating Activities	-29	-29	-41	-29	-25	-19	-40	-23	-27	-25	-44
Net Income / (Loss) Continuing Operations	-44	-42	-141	-32	-44	-43	-49	-47	-53	-48	-56
Consolidated Net Income / (Loss)	-44	-42	-141	-32	-44	-43	-49	-47	-53	-48	-56
Depreciation Expense	0.44	0.42	0.41	0.39	0.39	0.38	0.38	0.38	0.30	0.27	0.25
Amortization Expense	4.30	-9.84	-1.37	-5.52	-2.47	-2.14	-1.79	-1.18	-1.70	-1.86	-1.44
Non-Cash Adjustments To Reconcile Net Income	12	13	104	11	16	16	18	20	25	25	29
Changes in Operating Assets and Liabilities, net	-1.71	8.87	-2.68	-2.45	4.19	10	-7.83	4.03	2.75	-0.82	-17
Net Cash From Investing Activities	-95	23	30	-8.56	-91	21	25	54	-246	30	57
Net Cash From Continuing Investing Activities	-95	23	30	-8.56	-91	21	25	54	-246	30	57
Purchase of Investments	-169	-41	0.00	-66	-136	-66	-34	-27	-268	-20	-42
Sale and/or Maturity of Investments	75	63	70	58	45	88	58	81	62	52	99
Net Cash From Financing Activities	73	2.42	4.24	146	2.49	38	32	-0.89	189	-2.95	-5.40
Net Cash From Continuing Financing Activities	73	2.42	4.24	146	2.49	38	32	-0.89	189	-2.95	-5.40
Repayment of Debt	-2.17	-2.57	-2.78	-2.97	-3.34	-3.81	-4.62	-4.33	-5.57	-5.40	-4.29
Issuance of Common Equity	49	-	0.67	-	0.60	39	35	-	189	0.00	1.25
Other Financing Activities, net	1.58	5.00	6.35	10	5.23	2.99	2.23	3.44	5.49	2.45	-2.36
Effect of Exchange Rate Changes	0.08	-0.19	-0.07	-0.30	-0.60	0.98	-0.00	-0.28	0.30	0.06	0.45

This table presents Rhythm Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2016	12/31/2017	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Total Assets	12	152	309	187	330	382	333	392	480
Total Current Assets	11	151	302	182	308	354	308	374	467
Cash & Equivalents	6.54	34	62	101	59	128	60	89	54
Restricted Cash	-	-	-	-	-	-	-	0.46	0.52
Short-Term Investments	4.00	114	230	72	236	206	216	231	335
Accounts Receivable	-	-	-	-	1.03	6.22	15	19	26
Inventories, net	-	-	-	-	0.11	2.92	8.62	19	26
Prepaid Expenses	0.64	2.59	9.95	8.88	12	12	8.93	16	26
Plant, Property, & Equipment, net	0.93	0.84	3.67	3.20	2.81	2.20	1.34	0.63	1.10
Total Noncurrent Assets	0.23	0.23	2.45	2.21	18	26	23	17	12
Long-Term Investments	-	-	-	-	12	17	15	7.33	3.29
Intangible Assets	-	-	-	0.00	4.66	7.88	7.03	6.17	5.32
Other Noncurrent Operating Assets	0.23	0.23	2.45	2.21	1.85	1.51	1.11	3.48	3.05
Total Liabilities & Shareholders' Equity	12	152	309	187	330	382	333	392	480
Total Liabilities	5.04	6.95	28	21	45	118	163	228	210
Total Current Liabilities	4.73	6.72	24	18	43	40	55	116	106
Short-Term Debt	-	-	-	-	-	-	0.00	1.54	7.30
Accounts Payable	2.00	2.43	10	4.90	5.74	4.80	4.89	12	14
Accrued Expenses	2.66	4.21	14	13	30	33	48	63	84
Current Deferred Revenue	0.08	0.08	-	-	7.00	1.43	1.29	1.29	0.19
Other Current Liabilities	-	-	0.47	0.54	0.61	0.68	0.77	38	0.65
Total Noncurrent Liabilities	0.31	0.23	3.09	2.55	1.95	78	108	112	104
Long-Term Debt	-	-	-	-	-	-	106	108	101
Other Noncurrent Operating Liabilities	-	-	3.09	2.55	1.95	2.60	1.64	3.94	3.34
Commitments & Contingencies	0.00	0.00	0.00	0.00	-	-	0.00	0.00	0.00
Redeemable Noncontrolling Interest	40	0.00	-	-	-	-	0.00	143	131
Total Equity & Noncontrolling Interests	-33	145	281	167	284	264	170	22	139
Total Preferred & Common Equity	-33	145	281	167	284	264	170	22	139
Preferred Stock	-	-	-	-	-	0.00	-	-	0.00
Total Common Equity	-33	145	281	167	284	264	170	22	139
Common Stock	44	255	606	626	813	974	1,064	1,177	1,492
Retained Earnings	-77	-110	-325	-459	-529	-710	-895	-1,155	-1,352
Accumulated Other Comprehensive Income / (Loss)	-	-	0.00	0.05	-0.00	-0.09	0.13	-0.04	-0.80

This table presents Rhythm Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024	3/31/2025	6/30/2025	9/30/2025	3/31/2026
Total Assets	390	346	310	354	259	382	364	387	373	507	442
Total Current Assets	362	318	284	329	236	357	340	369	361	495	430
Cash & Equivalents	185	110	116	65	53	162	48	106	136	52	62
Restricted Cash	-	-	-	-	-	0.46	0.46	0.46	0.53	0.67	0.60
Short-Term Investments	163	185	138	235	148	157	251	208	155	364	278
Accounts Receivable	3.33	8.12	14	15	15	18	19	18	26	33	34
Inventories, net	-	5.49	6.18	7.76	8.51	12	14	19	19	22	29
Prepaid Expenses	11	9.65	10	7.64	11	8.64	8.75	18	25	24	27
Plant, Property, & Equipment, net	2.43	2.00	1.77	1.55	1.15	0.97	0.80	0.46	0.30	0.24	1.07
Total Noncurrent Assets	25	26	24	23	22	23	22	16	11	11	11
Long-Term Investments	16	17	16	15	14	13	12	7.14	2.22	2.47	2.52
Intangible Assets	8.10	7.67	7.46	7.24	6.82	6.60	6.39	5.96	5.75	5.53	5.11
Other Noncurrent Operating Assets	1.60	1.42	1.32	1.22	1.13	3.70	3.59	3.37	3.26	3.16	2.94
Total Liabilities & Shareholders' Equity	390	346	310	354	259	382	364	387	373	507	442
Total Liabilities	108	126	128	157	197	202	211	224	239	211	205
Total Current Liabilities	33	46	46	50	54	55	98	112	129	104	103
Short-Term Debt	-	-	-	-	-	-	-	1.59	3.78	5.56	10
Accounts Payable	4.93	13	8.38	3.84	7.55	4.54	4.89	12	16	14	12
Accrued Expenses	26	31	36	44	45	48	55	59	69	84	80
Current Deferred Revenue	1.76	1.43	1.29	1.29	1.29	1.29	1.29	0.00	0.00	0.00	0.05
Other Current Liabilities	0.66	0.71	0.73	0.75	0.79	1.18	37	39	41	0.62	0.68
Total Noncurrent Liabilities	75	80	82	107	143	147	113	112	110	107	102
Long-Term Debt	73	-	-	-	-	-	-	108	106	103	98
Other Noncurrent Operating Liabilities	2.36	2.37	2.21	1.88	36	39	4.03	3.84	3.68	3.52	3.16
Commitments & Contingencies	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00
Redeemable Noncontrolling Interest	-	-	-	-	-	140	141	144	145	147	115
Total Equity & Noncontrolling Interests	281	220	182	197	62	39	11	19	-12	149	123
Total Preferred & Common Equity	281	220	182	197	62	39	11	19	-12	149	123
Preferred Stock	-	-	-	-	-	0.00	0.00	-	-	-	0.00
Total Common Equity	281	220	182	197	62	39	11	19	-12	149	123
Common Stock	949	982	991	1,051	1,098	1,108	1,124	1,224	1,242	1,454	1,530
Retained Earnings	-668	-762	-809	-853	-1,036	-1,068	-1,112	-1,205	-1,251	-1,304	-1,408
Accumulated Other Comprehensive Income / (Loss)	-0.34	-0.01	-0.01	-0.11	-0.18	-0.62	-0.60	-0.05	-2.25	-0.93	0.44

This table displays calculated financial ratios and metrics derived from Rhythm Pharmaceuticals' official financial filings.

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Period end date	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024	12/31/2025
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	649.46%	227.56%	68.06%	45.83%
EBITDA Growth	0.00%	-132.65%	-32.18%	-128.99%	-79.41%	2.87%	49.29%	-160.95%	-7.03%	-36.78%	24.92%
EBIT Growth	0.00%	-133.95%	-32.31%	-128.79%	-79.46%	2.95%	48.70%	-155.72%	-2.90%	-39.19%	25.01%
NOPAT Growth	0.00%	-145.01%	-25.12%	-141.94%	-86.18%	6.46%	-24.52%	-5.35%	-2.90%	-44.02%	27.68%
Net Income Growth	0.00%	-133.65%	-30.29%	-119.72%	-90.01%	4.78%	48.05%	-160.18%	-1.97%	-41.11%	24.58%
EPS Growth	0.00%	-141.53%	0.70%	15.55%	-61.51%	21.24%	53.95%	100.00%	0.00%	-35.63%	28.34%
Operating Cash Flow Growth	0.00%	-232.79%	-26.88%	-110.64%	-97.81%	0.63%	-19.69%	-18.78%	21.49%	16.36%	-1.58%
Free Cash Flow Firm Growth	0.00%	0.00%	-52.13%	-156.97%	-55.98%	-11.04%	-1.99%	39.44%	-220.96%	26.52%	-18.43%
Invested Capital Growth	0.00%	0.00%	-1.39%	100.00%	0.00%	45.24%	-259.50%	-280.48%	82.56%	-261.35%	73.06%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	135.90%	41.84%	24.92%	15.64%	8.85%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	-25.85%	-16,423.80%	-19,429.30%	-29.68%	2.83%	-5.28%	-3.13%	-1.91%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	-25.97%	0.00%	0.00%	-29.40%	5.10%	0.59%	-0.90%	-2.05%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	-25.97%	0.00%	0.00%	-10.33%	4.73%	0.45%	0.01%	-3.12%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	-25.35%	0.00%	0.00%	-12.93%	0.21%	0.46%	-0.65%	-2.17%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-106.03%	0.00%	0.00%	-9.38%	100.00%	0.00%	0.00%	-0.65%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-6.15%	-26.75%	-10.08%	2.48%	-8.43%	3.60%	3.28%	8.47%	-6.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-1,285.64%	-1,713.52%	-6.93%	55.22%	-803.70%	-1.59%	36.54%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	100.00%	-9.95%	-29.23%	-35.46%	-825.78%	87.20%	65.86%	-0.01%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	81.01%	90.98%	87.99%	89.73%	89.73%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,184.56%	-760.64%	-248.53%	-202.27%	-103.25%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-5,391.85%	-757.92%	-238.10%	-204.04%	-101.19%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,221.27%	-757.92%	-238.10%	-197.20%	-100.52%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,207.10%	-766.22%	-238.52%	-200.27%	-103.57%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	50.00%	100.00%	100.00%	100.00%	100.31%	100.13%	100.25%
Interest Burden Percent	100.00%	99.87%	98.35%	94.45%	200.00%	98.11%	99.36%	101.10%	99.87%	101.42%	102.77%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-354.56%	-44.33%	-102.31%	-100.16%	-59.88%	-30.89%	-66.05%	-85.10%	-155.91%	-90.45%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-27.12%	-50.32%	-51.55%	-70.79%	-43.73%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-26.95%	-50.88%	-51.64%	-71.89%	-45.05%
Return on Common Equity (ROCE)	0.00%	1,589.02%	-32.67%	-102.31%	-100.16%	-59.88%	-30.89%	-66.05%	-85.10%	-89.30%	-33.47%
Return on Equity Simple (ROE_SIMPLE)	0.00%	79.11%	-23.28%	0.00%	-50.08%	-80.46%	-24.50%	-68.54%	-108.79%	-1,199.33%	0.00%
Net Operating Profit after Tax (NOPAT)	-7.40	-18	-23	-55	-102	-96	-119	-125	-129	-186	-134
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3,774.30%	-530.54%	-166.67%	-142.82%	-70.83%
Net Nonoperating Expense Percent (NNEP)	0.00%	-146.76%	-13.89%	-25.89%	-26.35%	-16.50%	20.62%	-16.97%	-20.81%	-37.07%	-24.70%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-47.46%	-46.77%	-141.29%	-54.36%
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	18.99%	9.02%	12.01%	10.27%	10.27%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	2,171.40%	389.34%	151.80%	110.90%	102.73%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	3,301.46%	459.56%	174.29%	182.87%	88.19%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	5,472.86%	848.90%	326.09%	293.76%	190.92%
Earnings before Interest and Taxes (EBIT)	-11	-26	-34	-78	-141	-137	-70	-179	-184	-257	-191
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-11	-26	-34	-78	-140	-136	-69	-180	-192	-263	-196
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	5.48	0.00	3.59	7.89	1.77	6.21	16.00	158.33	51.37
Price to Tangible Book Value (P/TBV)	0.00	0.00	5.48	0.00	3.59	7.89	1.80	6.40	16.69	221.17	53.41
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	159.06	69.42	35.09	26.44	37.65
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	61.83	54.61	32.70	25.86	36.84
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.63	0.67	0.40
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.63	0.66	0.37
Financial Leverage	0.00	-1.45	-1.04	-1.02	-1.04	-1.04	-1.06	-1.20	-1.23	-1.21	-1.16
Leverage Ratio	0.00	1.69	1.08	1.05	1.10	1.11	1.15	1.30	1.65	2.17	2.01
Compound Leverage Factor	0.00	1.69	1.06	0.99	2.20	1.09	1.14	1.31	1.65	2.20	2.06
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	38.47%	40.02%	28.60%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.56%	1.93%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	38.47%	39.46%	26.67%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	548.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	52.06%	34.63%
Common Equity to Total Capital	0.00%	-448.17%	100.00%	0.00%	100.00%	100.00%	100.00%	100.00%	61.53%	7.92%	36.77%
Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.55	-0.42	-0.55
Net Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.96	0.83	1.45
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.55	-0.41	-0.51
Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.82	-0.59	-0.80
Net Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.43	1.18	2.12
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-0.82	-0.58	-0.75
Altman Z-Score	0.00	0.00	67.85	0.00	20.10	33.58	4.66	5.23	5.55	3.91	16.44
Noncontrolling Interest Sharing Ratio	0.00%	548.17%	26.30%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	42.72%	63.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	2.36	22.42	0.00	12.39	10.10	7.10	8.90	5.58	3.24	4.41
Quick Ratio	0.00	2.23	22.04	0.00	11.98	9.60	6.81	8.53	5.27	2.94	3.92
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-15	-23	-58	-91	-101	-103	-62	-200	-147	-174
Operating Cash Flow to CapEx	-41,041.18%	-2,196.69%	-22,150.38%	-8,595.01%	-3,626.29%	-57,000.00%	-33,641.24%	-61,718.15%	-289,695.74%	0.00%	-12,137.99%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-11.97	-14.38	-7.13	-8.45
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-33.35	-9.80	-5.53	-5.62
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-33.40	-9.80	-5.53	-5.67
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.01	0.07	0.22	0.36	0.44
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	6.52	7.34	7.80	8.51
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	1.41	1.61	0.98	0.88
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	1.05	9.44	43.77	131.91	218.61
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.11	0.41	1.92	1.55	1.48
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	55.97	49.71	46.81	42.89
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	259.08	226.43	373.59	416.59
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	3,240.82	901.29	189.96	234.99	246.01
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	-3,240.82	-586.25	86.18	185.41	213.47
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	-3.25	-3.29	0.00	-11	-6.26	-23	-86	-15	-54	-15
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	-0.22	-0.44	-1.54	-3.78	-5.54
Increase / (Decrease) in Invested Capital	0.00	-3.25	-0.05	3.29	-11	5.18	-16	-63	71	-39	39
Enterprise Value (EV)	0.00	0.00	645	925	716	1,141	195	1,291	2,532	3,365	6,990
Market Capitalization	0.00	0.00	793	925	1,009	1,314	502	1,641	2,717	3,440	7,143
Book Value per Share	$0.00	($3.21)	$5.31	$0.00	$6.40	$3.77	$5.65	$4.69	$2.87	$0.35	$2.08
Tangible Book Value per Share	$0.00	($3.21)	$5.31	$0.00	$6.40	$3.77	$5.56	$4.55	$2.75	$0.25	$2.00
Total Capital	0.00	7.30	145	0.00	281	167	284	264	276	274	378
Total Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	106	110	108
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	106	108	101
Net Debt	0.00	-11	-148	0.00	-292	-173	-307	-350	-185	-219	-285
Capital Expenditures (CapEx)	0.02	1.06	0.13	0.72	3.39	0.21	0.43	0.28	0.05	0.00	0.95
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-4.09	-4.13	0.00	-14	-9.12	-30	-19	-23	-61	-21
Debt-free Net Working Capital (DFNWC)	0.00	6.44	144	0.00	278	164	265	314	253	260	368
Net Working Capital (NWC)	0.00	6.44	144	0.00	278	164	265	314	253	259	361
Net Nonoperating Expense (NNE)	3.67	7.74	11	19	39	38	-49	56	56	75	62
Net Nonoperating Obligations (NNO)	0.00	-11	-148	0.00	-292	-173	-307	-350	-185	-219	-285
Total Depreciation and Amortization (D&A)	0.00	0.14	0.22	0.44	0.83	0.69	1.16	-0.64	-8.08	-6.60	-5.18
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-947.84%	-79.79%	-29.42%	-46.73%	-11.17%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	8,400.76%	1,330.18%	326.84%	199.98%	194.07%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	8,400.76%	1,330.18%	326.84%	198.79%	190.23%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.18)	($2.85)	($2.83)	($2.39)	$0.00	($3.04)	($1.40)	($3.47)	($3.20)	($4.34)	($3.11)
Adjusted Weighted Average Basic Shares Outstanding	10.20M	10.20M	27.28M	34.43M	0.00	50.18M	49.60M	52.12M	57.67M	61.00M	64.98M
Adjusted Diluted Earnings per Share	($1.18)	($2.85)	($2.83)	($2.39)	$0.00	($3.04)	($1.40)	($3.47)	($3.20)	($4.34)	($3.11)
Adjusted Weighted Average Diluted Shares Outstanding	10.20M	10.20M	27.28M	34.43M	0.00	50.18M	49.60M	52.12M	57.67M	61.00M	64.98M
Adjusted Basic & Diluted Earnings per Share	($1.18)	($2.85)	($2.83)	($2.39)	$0.00	($3.04)	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	10.20M	10.20M	13.27M	31.00M	0.00	44.13M	49.60M	56.75M	60.14M	63.22M	68.29M
Normalized Net Operating Profit after Tax (NOPAT)	-7.40	-18	-23	-55	-102	-96	-119	-125	-129	-186	-134
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-3,774.30%	-530.54%	-166.67%	-142.82%	-70.83%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-2,207.10%	-766.22%	-237.79%	-200.00%	-103.31%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-34.45	-13.27	-12.45	-9.27
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-24.11	-9.29	-9.02	-6.53
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-34.50	-13.27	-12.45	-9.31
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-24.17	-9.29	-9.02	-6.58
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Rhythm Pharmaceuticals' official financial filings.

Metric	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Period end date	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026
DEI Shares Outstanding	-	-	-	-	-	-	-	-	-	-	68,285,039.00
DEI Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	68,285,039.00
DEI Earnings Per Adjusted Shares Outstanding	-	-	-	-	-	-	-	-	-	-	-0.83
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	425.30%	175.70%	126.41%	51.28%	47.76%	72.61%	25.94%	66.80%	54.28%	36.87%	83.81%
EBITDA Growth	-6.26%	-11.13%	-166.64%	28.90%	-13.98%	11.02%	65.04%	-34.59%	-19.82%	-13.83%	-12.63%
EBIT Growth	-11.29%	0.73%	-165.16%	32.91%	2.98%	-5.12%	65.81%	-39.79%	-22.39%	-14.85%	-13.47%
NOPAT Growth	-11.93%	1.98%	-166.29%	13.14%	0.15%	0.04%	66.40%	-11.90%	-19.98%	-14.08%	-11.40%
Net Income Growth	-8.08%	2.02%	-170.94%	30.92%	1.18%	-4.07%	64.99%	-44.55%	-21.23%	-9.64%	-12.41%
EPS Growth	3.80%	0.00%	0.00%	32.93%	3.95%	0.00%	65.53%	-36.36%	-12.33%	-2.82%	-2.47%
Operating Cash Flow Growth	37.75%	13.58%	-11.83%	29.24%	13.80%	35.86%	0.96%	19.82%	-5.58%	-34.73%	-9.50%
Free Cash Flow Firm Growth	320.22%	-395.72%	-215.43%	15.11%	-86.13%	110.21%	-279.36%	-456.07%	-1,794.83%	-811.40%	35.34%
Invested Capital Growth	-1,161.82%	82.56%	-67.54%	-76.02%	-35.42%	-261.35%	67.75%	67.02%	90.80%	73.06%	104.73%
Revenue Q/Q Growth	17.08%	7.69%	7.15%	11.98%	14.35%	25.80%	-21.82%	48.31%	5.76%	11.61%	4.99%
EBITDA Q/Q Growth	23.10%	-28.23%	-196.06%	73.43%	-23.28%	-0.10%	-9.19%	9.24%	-20.78%	9.64%	-13.71%
EBIT Q/Q Growth	5.38%	6.91%	-240.94%	77.56%	-36.84%	-0.86%	-10.38%	8.24%	-19.81%	10.26%	-15.02%
NOPAT Q/Q Growth	5.69%	6.11%	-238.96%	71.06%	-8.42%	6.00%	-13.94%	3.63%	-16.24%	10.62%	-11.26%
Net Income Q/Q Growth	5.44%	5.73%	-239.57%	77.18%	-35.27%	0.72%	-14.24%	5.79%	-13.45%	10.21%	-17.12%
EPS Q/Q Growth	7.32%	0.00%	0.00%	0.00%	-32.73%	0.00%	0.00%	7.41%	-9.33%	10.98%	-13.70%
Operating Cash Flow Q/Q Growth	28.81%	-0.45%	-38.66%	28.64%	13.28%	25.26%	-114.12%	42.22%	-14.19%	4.63%	-74.03%
Free Cash Flow Firm Q/Q Growth	134.51%	-229.79%	-653.53%	204.45%	-71.74%	-4.43%	-1,444.76%	1.97%	-34.52%	59.88%	-22.22%
Invested Capital Q/Q Growth	-34.49%	87.20%	-26.71%	0.38%	-3.47%	65.86%	8.36%	-1.86%	71.14%	-0.01%	116.09%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	89.28%	86.66%	89.19%	89.87%	88.49%	90.95%	88.85%	88.57%	89.28%	91.61%	88.09%
EBITDA Margin	-174.95%	-208.32%	-527.61%	-125.19%	-134.96%	-107.39%	-149.99%	-91.79%	-104.82%	-84.87%	-91.91%
Operating Margin	-195.31%	-170.29%	-538.71%	-139.20%	-131.98%	-98.62%	-143.73%	-93.39%	-102.64%	-82.20%	-87.11%
EBIT Margin	-196.02%	-169.46%	-536.69%	-107.56%	-128.71%	-103.20%	-145.69%	-90.14%	-102.11%	-82.10%	-89.94%
Profit (Net Income) Margin	-196.25%	-171.80%	-544.43%	-110.95%	-131.25%	-103.58%	-151.35%	-96.14%	-103.13%	-82.97%	-92.56%
Tax Burden Percent	100.84%	100.47%	100.21%	101.51%	99.22%	99.80%	100.16%	100.73%	100.21%	99.93%	100.99%
Interest Burden Percent	99.28%	100.90%	101.23%	101.62%	102.78%	100.58%	103.71%	105.89%	100.79%	101.13%	101.90%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-77.52%	-85.10%	-194.69%	-143.42%	-147.88%	-155.91%	-150.20%	-116.97%	-85.80%	-90.45%	-101.16%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-8,115.55%
Operating Return on Assets (OROA)	-32.67%	-36.69%	-163.28%	-31.65%	-40.36%	-37.04%	-61.80%	-37.34%	-40.90%	-35.71%	-47.12%
Return on Assets (ROA)	-32.71%	-37.20%	-165.63%	-32.65%	-41.15%	-37.18%	-64.20%	-39.83%	-41.31%	-36.09%	-48.49%
Return on Common Equity (ROCE)	-77.52%	-85.10%	-194.69%	-87.86%	-88.13%	-89.30%	-53.84%	-10.25%	-30.62%	-33.47%	-35.81%
Return on Equity Simple (ROE_SIMPLE)	-93.96%	0.00%	-444.73%	-659.40%	-2,308.58%	0.00%	-890.53%	0.00%	0.00%	0.00%	0.00%
Net Operating Profit after Tax (NOPAT)	-31	-29	-98	-28	-31	-29	-33	-32	-37	-33	-37
NOPAT Margin	-136.72%	-119.21%	-377.10%	-97.44%	-92.39%	-69.03%	-100.61%	-65.37%	-71.85%	-57.54%	-60.97%
Net Nonoperating Expense Percent (NNEP)	-4.43%	-4.77%	-16.51%	-1.31%	-4.13%	-7.17%	-7.76%	-5.78%	-5.17%	-5.79%	-8.48%
Return On Investment Capital (ROIC_SIMPLE)	-	-10.47%	-	-	-	-21.95%	-25.61%	-32.39%	-14.30%	-13.32%	-15.84%
Cost of Revenue to Revenue	10.72%	13.34%	10.81%	10.13%	11.51%	9.05%	11.15%	11.43%	10.72%	8.39%	11.91%
SG&A Expenses to Revenue	135.42%	133.60%	132.41%	125.23%	106.39%	91.15%	119.52%	94.73%	102.20%	100.40%	105.79%
R&D to Revenue	149.17%	123.35%	495.49%	103.84%	114.07%	98.42%	113.05%	87.23%	89.72%	73.41%	69.41%
Operating Expenses to Revenue	284.59%	256.95%	627.90%	229.07%	220.47%	189.57%	232.57%	181.96%	191.92%	173.81%	175.20%
Earnings before Interest and Taxes (EBIT)	-44	-41	-139	-31	-43	-43	-48	-44	-52	-47	-54
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-39	-50	-137	-36	-45	-45	-49	-45	-54	-49	-55
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	6.61	16.00	42.32	63.63	285.58	158.33	176.75	0.00	45.07	51.37	48.32
Price to Tangible Book Value (P/TBV)	6.86	16.69	47.58	76.46	663.52	221.17	257.87	0.00	46.81	53.41	50.41
Price to Revenue (P/Rev)	21.05	35.09	28.35	24.60	28.46	26.44	24.47	25.72	38.48	37.65	27.35
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2,485.34
Enterprise Value to Revenue (EV/Rev)	15.98	32.70	26.01	22.71	26.96	25.86	23.97	25.48	37.54	36.84	26.79
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.63	0.00	0.00	0.00	0.67	0.67	0.82	0.37	0.40	0.46
Long-Term Debt to Equity	0.00	0.63	0.00	0.00	0.00	0.66	0.66	0.79	0.35	0.37	0.41
Financial Leverage	-1.26	-1.23	-1.87	-1.66	-1.79	-1.21	-1.90	-1.65	-1.39	-1.16	-1.12
Leverage Ratio	1.55	1.65	2.15	1.91	2.05	2.17	2.87	2.41	1.94	2.01	2.07
Compound Leverage Factor	1.54	1.66	2.17	1.94	2.11	2.18	2.98	2.55	1.96	2.03	2.11
Debt to Total Capital	0.00%	38.47%	0.00%	0.00%	0.00%	40.02%	40.18%	45.11%	26.93%	28.60%	31.34%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.56%	0.58%	1.55%	1.37%	1.93%	2.93%
Long-Term Debt to Total Capital	0.00%	38.47%	0.00%	0.00%	0.00%	39.46%	39.59%	43.56%	25.56%	26.67%	28.41%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	78.08%	92.66%	52.06%	52.87%	59.78%	36.29%	34.63%	33.15%
Common Equity to Total Capital	100.00%	61.53%	100.00%	21.92%	7.34%	7.92%	6.95%	-4.89%	36.78%	36.77%	35.51%
Debt to EBITDA	0.00	-0.55	0.00	0.00	0.00	-0.42	-0.64	-0.60	-0.57	-0.55	-0.54
Net Debt to EBITDA	0.00	0.96	0.00	0.00	0.00	0.83	1.24	1.00	1.61	1.45	1.16
Long-Term Debt to EBITDA	0.00	-0.55	0.00	0.00	0.00	-0.41	-0.63	-0.58	-0.54	-0.51	-0.49
Debt to NOPAT	0.00	-0.82	0.00	0.00	0.00	-0.59	-0.91	-0.88	-0.84	-0.80	-0.79
Net Debt to NOPAT	0.00	1.43	0.00	0.00	0.00	1.18	1.76	1.48	2.38	2.12	1.70
Long-Term Debt to NOPAT	0.00	-0.82	0.00	0.00	0.00	-0.58	-0.89	-0.85	-0.79	-0.75	-0.71
Altman Z-Score	2.33	6.97	1.75	4.45	5.55	5.70	5.37	6.16	16.38	17.43	13.93
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	38.74%	40.40%	42.72%	64.16%	91.24%	64.31%	63.00%	64.60%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.57	5.58	4.35	6.53	3.49	3.24	3.30	2.79	4.75	4.41	4.17
Quick Ratio	6.26	5.27	3.99	6.15	3.25	2.94	2.97	2.45	4.31	3.92	3.63
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	77	-100	-36	38	11	10	-137	-134	-180	-72	-88
Operating Cash Flow to CapEx	-2,925,100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	24.38	-22.75	-7.59	8.19	2.03	1.70	-25.30	-23.06	-38.06	-15.69	-19.31
Operating Cash Flow to Interest Expense	-9.29	-6.71	-8.57	-6.32	-4.81	-3.14	-7.46	-4.01	-5.61	-5.50	-9.64
Operating Cash Flow Less CapEx to Interest Expense	-9.29	-6.71	-8.57	-6.32	-4.81	-3.14	-7.46	-4.01	-5.61	-5.50	-9.64
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.17	0.22	0.30	0.29	0.31	0.36	0.42	0.41	0.40	0.44	0.52
Accounts Receivable Turnover	6.94	7.34	8.06	6.48	6.65	7.80	8.42	7.15	6.66	8.51	8.35
Inventory Turnover	0.00	1.61	1.53	1.25	1.18	0.98	1.02	1.09	1.03	0.88	0.96
Fixed Asset Turnover	31.22	43.77	58.37	74.13	95.93	131.91	169.91	246.12	335.90	218.61	284.43
Accounts Payable Turnover	1.62	1.92	1.02	1.76	2.94	1.55	1.46	1.64	2.00	1.48	1.90
Days Sales Outstanding (DSO)	52.61	49.71	45.29	56.35	54.89	46.81	43.36	51.05	54.79	42.89	43.71
Days Inventory Outstanding (DIO)	0.00	226.43	238.95	290.94	308.42	373.59	357.36	335.20	355.62	416.59	380.59
Days Payable Outstanding (DPO)	225.57	189.96	356.82	206.95	124.27	234.99	249.97	222.90	182.91	246.01	192.10
Cash Conversion Cycle (CCC)	-172.96	86.18	-72.58	140.34	239.04	185.41	150.75	163.35	227.49	213.47	232.20
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-117	-15	-153	-153	-158	-54	-49	-50	-15	-15	2.34
Invested Capital Turnover	-0.98	-1.54	-0.75	-0.85	-0.82	-3.78	-1.35	-1.54	-2.02	-5.54	-9.21
Increase / (Decrease) in Invested Capital	-108	71	-62	-66	-41	-39	104	102	144	39	52
Enterprise Value (EV)	990	2,532	2,391	2,311	3,033	3,365	3,281	3,982	6,544	6,990	5,818
Market Capitalization	1,304	2,717	2,606	2,504	3,203	3,440	3,349	4,020	6,708	7,143	5,939
Book Value per Share	$3.47	$2.87	$1.02	$0.65	$0.18	$0.35	$0.30	($0.19)	$2.24	$2.08	$1.80
Tangible Book Value per Share	$3.34	$2.75	$0.91	$0.54	$0.08	$0.25	$0.21	($0.28)	$2.16	$2.00	$1.73
Total Capital	197	276	62	179	153	274	273	243	405	378	346
Total Debt	0.00	106	0.00	0.00	0.00	110	110	110	109	108	108
Total Long-Term Debt	0.00	106	0.00	0.00	0.00	108	108	106	103	101	98
Net Debt	-314	-185	-215	-332	-311	-219	-213	-184	-310	-285	-235
Capital Expenditures (CapEx)	0.00	-0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-20	-23	-20	-17	-56	-61	-56	-57	-21	-21	-4.20
Debt-free Net Working Capital (DFNWC)	279	253	182	303	243	260	259	235	396	368	337
Net Working Capital (NWC)	279	253	182	303	243	259	257	231	391	361	327
Net Nonoperating Expense (NNE)	13	13	43	3.93	13	14	17	15	16	15	19
Net Nonoperating Obligations (NNO)	-314	-185	-215	-332	-311	-219	-213	-184	-310	-285	-235
Total Depreciation and Amortization (D&A)	4.74	-9.42	2.36	-5.13	-2.08	-1.76	-1.40	-0.80	-1.39	-1.58	-1.18
Debt-free, Cash-free Net Working Capital to Revenue	-32.59%	-29.42%	-21.33%	-16.65%	-49.87%	-46.73%	-40.84%	-36.19%	-11.83%	-11.17%	-1.94%
Debt-free Net Working Capital to Revenue	450.21%	326.84%	197.54%	297.34%	215.71%	199.98%	189.28%	150.37%	227.20%	194.07%	155.19%
Net Working Capital to Revenue	450.21%	326.84%	197.54%	297.34%	215.71%	198.79%	188.12%	147.95%	224.02%	190.23%	150.53%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.76)	($0.70)	($2.35)	($0.55)	($0.73)	($0.71)	($0.81)	($0.75)	($0.82)	($0.73)	($0.83)
Adjusted Weighted Average Basic Shares Outstanding	57.87M	57.67M	60.14M	61.01M	61.22M	61.00M	63.06M	63.68M	66.26M	64.98M	67.97M
Adjusted Diluted Earnings per Share	($0.76)	$0.00	$0.00	($0.55)	($0.73)	$0.00	($0.81)	($0.75)	($0.82)	($0.73)	($0.83)
Adjusted Weighted Average Diluted Shares Outstanding	57.87M	57.67M	60.97M	61.01M	61.22M	61.00M	63.06M	63.68M	66.26M	64.98M	67.97M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	59.10M	60.14M	60.97M	61.13M	61.46M	63.22M	63.62M	66.42M	66.74M	68.29M	68.53M
Normalized Net Operating Profit after Tax (NOPAT)	-31	-29	-98	-28	-31	-29	-33	-32	-37	-33	-37
Normalized NOPAT Margin	-136.72%	-119.21%	-377.10%	-97.44%	-92.39%	-69.03%	-100.61%	-65.37%	-71.85%	-57.54%	-60.97%
Pre Tax Income Margin	-194.61%	-170.99%	-543.27%	-109.30%	-132.28%	-103.79%	-151.11%	-95.45%	-102.91%	-83.03%	-91.65%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-14.01	-9.38	-29.31	-6.79	-8.16	-7.19	-8.81	-7.52	-11.05	-10.19	-11.80
NOPAT to Interest Expense	-9.77	-6.60	-20.59	-6.16	-5.86	-4.81	-6.08	-5.45	-7.77	-7.14	-8.00
EBIT Less CapEx to Interest Expense	-14.01	-9.38	-29.31	-6.79	-8.16	-7.19	-8.81	-7.52	-11.05	-10.19	-11.80
NOPAT Less CapEx to Interest Expense	-9.77	-6.60	-20.59	-6.16	-5.86	-4.81	-6.08	-5.45	-7.77	-7.14	-8.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials Breakdown Chart

Key Financial Trends

Rhythm Pharmaceuticals, Inc. (RYTM) has shown a pattern of growing quarterly revenue in 2025 alongside persistent net losses and heavy operating spending. The company’s balance sheet reflects a expanding asset base and a still-leveraged liability position, with cash flows historically weighted toward investing activities and occasional liquidity support from investing inflows. Below is a concise, investor-focused view of key trends from the last four years, anchored by the latest Q4 2025 data and context from 2022–2024 quarters.

Revenue growth in 2025: Q4 2025 operating revenue reached $57.3 million, up from $41.8 million in Q4 2024, indicating a meaningful year-over-year expansion.
Strong gross margin in Q4 2025: Total gross profit was $52.45 million on $57.25 million of revenue, implying a gross margin around 92% for that quarter.
Cash from investing activities boosted by asset sales in Q4 2025: Net cash from continuing investing activities was +$30.35 million, driven by sale/maturity of investments (Sale of Investments) and related activity, contributing to overall liquidity.
Quarterly cash position improved in Q4 2025: Net change in cash and equivalents was +$2.07 million, showing a modest quarterly liquidity uptick despite ongoing losses.
Asset base trend: Total assets grew over the period, with sizable increases by 2025 (e.g., around $506.9 million by Q3 2025 versus earlier periods), reflecting balance-sheet expansion alongside revenue growth.
Non-cash adjustments and depreciation: The company reports non-cash adjustments (e.g., depreciation and amortization) and other non-cash items that meaningfully affect cash flow calculations, providing important reconciliation context for operating cash flow.
Debt profile remains in a modestly levered range: Long-term debt sits around the $100 million level across 2025 quarters, signaling ongoing leverage that may influence future financing considerations.
Net income remains negative: Q4 2025 net income attributable to common shareholders was −$48.9 million, continuing the broad pattern of annual losses observed in the period.
Operating cash flow remains negative in most quarters: Net cash from continuing operating activities was −$25.4 million in Q4 2025 and remained negative in prior quarters (e.g., −$26.6 million in Q3 2025, −$29.3 million in Q3 2025, etc.), signaling persistent cash burn from core operations.
Operating expenses outpace revenue growth: In Q4 2025, selling, general & administrative expenses and research & development expense combined were significantly higher than gross profit, contributing to negative operating income for the quarter.

05/14/26 05:13 AM ETAI Generated. May Contain Errors.

Rhythm Pharmaceuticals Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Rhythm Pharmaceuticals' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Rhythm Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$196.54 million in 2025, rising from -$11.07 million in 2015. The previous period was -$260.60 million in 2024. See Rhythm Pharmaceuticals' forecast for analyst expectations on what's next for the company.

Rhythm Pharmaceuticals' total operating income in 2025 was -$192.02 million, based on the following breakdown:

Total Gross Profit: $170.27 million
Total Operating Expenses: $362.28 million

Over the last 10 years, Rhythm Pharmaceuticals' total revenue changed from $0.00 in 2015 to $189.76 million in 2025, a change of 18,975,700,000.0%.

Rhythm Pharmaceuticals' total liabilities were at $210.17 million at the end of 2025, a 7.7% decrease from 2024, and a 4,068.4% increase since 2016.

In the past 8 years, Rhythm Pharmaceuticals' cash and equivalents has ranged from $6.54 million in 2016 to $127.68 million in 2022, and is currently $54.30 million as of their latest financial filing in 2025.

Over the last 10 years, Rhythm Pharmaceuticals' book value per share changed from 0.00 in 2015 to 2.08 in 2025, a change of 208.4%.

Related Companies

Financial statements for NASDAQ:RYTM last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rhythm Pharmaceuticals (RYTM) Financials

Financials Breakdown Chart

Key Financial Trends

Rhythm Pharmaceuticals Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Rhythm Pharmaceuticals (RYTM) Financials

Annual Income Statements for Rhythm Pharmaceuticals

Quarterly Income Statements for Rhythm Pharmaceuticals

Annual Cash Flow Statements for Rhythm Pharmaceuticals

Quarterly Cash Flow Statements for Rhythm Pharmaceuticals

Annual Balance Sheets for Rhythm Pharmaceuticals

Quarterly Balance Sheets for Rhythm Pharmaceuticals

Annual Metrics And Ratios for Rhythm Pharmaceuticals

Quarterly Metrics And Ratios for Rhythm Pharmaceuticals

Financials Breakdown Chart

Key Financial Trends

Rhythm Pharmaceuticals Financials - Frequently Asked Questions

When does Rhythm Pharmaceuticals' fiscal year end?

How has Rhythm Pharmaceuticals' net income changed over the last 10 years?

What is Rhythm Pharmaceuticals' operating income?

How has Rhythm Pharmaceuticals' revenue changed over the last 10 years?

How much debt does Rhythm Pharmaceuticals have?

How much cash does Rhythm Pharmaceuticals have?

How has Rhythm Pharmaceuticals' book value per share changed over the last 10 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools